Edison Oncology Holding, a Phase 2 biotech developing targeted small-molecule oncology therapies, filed on Friday with the SEC to raise up to $25 million in an initial public offering.
The Menlo Park, CA-based company plans to raise $25 million by offering 2.8 million shares (2% secondary) at a price range of $8 to $10. At the midpoint of the proposed range, Edison Oncology Holding would command a market cap of $75 million.
Edison Oncology is a clinical-stage biotech developing small-molecule drug candidates for oncology, including programs derived from reformulation, repurposing, and next-generation mechanism-of-action research. Its pipeline includes assets in Phase 1-2a evaluation targeting ARID1A-mutant cancers, replication-stress pathways, ErbB-driven tumors, and pediatric solid tumors. The company pursues conventional and 505(b)(2) regulatory pathways and conducts early-stage studies to evaluate safety, pharmacokinetics, and preliminary antitumor activity.
The Menlo Park, CA-based company was founded in 2018 and booked $446 thousand in revenue for the 12 months ended September 30, 2025. It plans to list on the NYSE American under the symbol EOHC. Konik Capital Partners is the sole bookrunner on the deal.
